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Abstract
Aims/hypothesis Long-term follow-up of the Steno-2 study demonstrated that intensified multifactorial intervention increased
median lifespan by 7.9 years and delayed incident cardiovascular disease by a median of 8.1 years compared with conventional
multifactorial intervention during 21.2 years of follow-up. In this post hoc analysis of data from the Steno-2 study, we aimed to
study the difference in direct medical costs associated with conventional vs intensified treatment.
Methods In 1993, 160 Danish individuals with type 2 diabetes and microalbuminuria were randomised to conventional or
intensified multifactorial target-driven intervention for 7.8 years. Information on direct healthcare costs was retrieved from health
registries, and the costs in the two groups of participants were compared by bootstrap t test analysis.
Results Over 21.2 years of follow-up, there was no difference in total direct medical costs between the intensified treatment
group, €12,126,900, and the conventional treatment group, €11,181,700 (p = 0.48). The mean cost per person-year during 1996–
2014 was significantly lower in the intensified treatment group (€8725 in the intensive group and €10,091 in the conventional
group, p = 0.045). The main driver of this difference was reduced costs associated with inpatient admissions related to cardio-
vascular disease (p = 0.0024).
Conclusions/interpretation Over a follow-up period of 21.2 years, we found no difference in total costs and reduced cost per
person-year associated with intensified multifactorial treatment for 7.8 years compared with conventional multifactorial treat-
ment. Considering the substantial gain in life-years and health benefits achieved with intensified treatment, we conclude that
intensified multifaceted intervention in high-risk individuals with type 2 diabetes seems to be highly feasible when balancing
healthcare costs and treatment benefits in a Danish healthcare setting.
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Abbreviations
CVD Cardiovascular disease
GP General practitioner
QALY Quality-adjusted life-year
Introduction
Cardiovascular disease (CVD) is the leading cause of death
and disability among individuals with type 2 diabetesmellitus,
with an incidence of almost three times that in the non-diabetic
population [1]. The cardiovascular morbidity associated with
type 2 diabetes poses a major health issue for individuals as
well as an economic burden on the healthcare system.
Individuals with type 2 diabetes have a life expectancy that
is reduced by around 5 years and a disability-free life expec-
tancy reduced by up to 9 years [2, 3].
Medical expenditure for Danish individuals with diabetes
is, on average, higher than that for people without diabetes,
ranging from 1.2 times higher for individuals with no compli-
cations to almost three times higher for individuals with severe
organ complications [4].
In 2011, the estimated total cost of healthcare attributed to
diabetes in Denmark was €1.64 billion [4]. The steadily in-
creasing number of individuals affected by type 2 diabetes on
a global scale [5, 6] means that the extent of type 2 diabetes-
related incident and prevalent cardiovascular morbidity and
mortality is increasing [7]; this will eventually become of
major concern to healthcare policymakers when managing
limited budgets.
In the Steno-2 study, an intensified multifactorial approach
was compared with a routine multifactorial intervention for
7.8 years in high-risk individuals with type 2 diabetes and
microalbuminuria. Outcomes were mortality and micro- and
macrovascular late complications, and the study had a total
follow-up of 21.2 years. At the end of follow-up, individuals
originally randomised to intensified therapy survived for a me-
dian of 7.9 years longer and incident CVD was delayed by
8.1 years with a relative risk reduction of 45% and an absolute
risk reduction of 20% [8]. Further, the risk of nephropathy [9]
and retinopathy [8], as well as heart failure [10], was substan-
tially decreased in the intensified therapy group.
In a study from 2008 with modelled data from the same
Steno-2 cohort, we predicted that intensified multifactorial
therapy together with outpatient consultations with endocri-
nologists would cost more than the conventional multifactori-
al therapy over a period of 30 years, but would still be cost-
effective because of the marked health benefits derived from
intensified care [11].
In this post hoc analysis, the aim was to compare the long-
term economic implications of intensified multifactorial treat-
ment and conventional multifactorial treatment with later inten-
sification in high-risk individuals with type 2 diabetes and
microalbuminuria from the perspective of a Danish healthcare
provider. Here, we have included the total realised direct medical
costs for the entire 21.2 years of follow-up in the Steno-2 study.
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Methods
The study was based on the randomised Steno-2 study.
Individuals were recruited from the Steno Diabetes Center,
Copenhagen, Denmark, during 1993–1994. All were diag-
nosed with type 2 diabetes and microalbuminuria (urinary
albumin excretion rate of 30–300 mg/24 h) and were thus at
high risk of developing micro- and macrovascular organ dam-
age [12]. A total of 160 individuals were randomly assigned
(using sealed envelopes) to either: intensified multifactorial
treatment at the Steno Diabetes Center that targeted all known
modifiable risk factors, using both behavioural and pharma-
cological approaches; or conventional multifactorial treatment
from their general practitioner (GP) following standard guide-
lines according to the 1988 recommendations of the Danish
Medical Society, which were applicable until 2000 [12]. For
an overview of risk factors treated and treatment targets in the
two groups, please refer to electronic supplementary material
(ESM) Table 1. After 7.8 years of intervention, all individuals
were instructed in intensified multifactorial treatment and the
trial continued as an observational follow-up study for an ad-
ditional 13.4 years. Between 2006 and 2014, one individual in
the conventional treatment group emigrated and was thus lost
to follow-up (see ESM Fig. 1). A detailed description of the
design of the Steno-2 study has previously been reported [12].
The protocol for the current analysis was approved by the
local ethics committee (Ethics Committee, Capital Region of
Denmark; protocol ID number: H-KA-99035-GS, add.
41104) and by the Danish Data Protection Agency (J. Nr
2015-41-4042) and the trial was registered (ClinicalTrials.
gov registration no. NCT00320008). Danish legislation does
not require specific participant consent to registry-based stu-
dies, but all participants provided written informed consent at
study visits.
Outcomes The primary outcome of the study was the diffe-
rence in total direct medical costs for the entire study duration
(1993–2014) between the original randomised groups
(Table 1). The secondary outcomes were the difference in
costs per person-year (Table 1), and the difference in costs
attributable to specific services outlined below (see Table 2).
As a confirmatory analysis, we performed similar evaluations
for the period 1996–2014 because of the quality of data (as
described in a subsequent section).
Total direct costs were divided into four categories.
‘Outpatient services’ covers any expenses attributable to con-
sultations and treatments at a hospital that are not counted as
an admission. ‘Inpatient admission services’ covers any ex-
penses attributable to hospital admissions. ‘Prescription
drugs’ covers expenses related to prescribed drugs. ‘Primary
health sector’ covers costs attributable to healthcare in general
practice and specialised medical professionals not employed
at a hospital, such as ophthalmologists, physiotherapists and
chiropractors.
Table 1 Total direct healthcare costs in the two treatment groups
Costs Sum of healthcare costs (€) p value
Intensive Conventional
All direct medical
1993–2014 12,126,900 11,181,700 0.48
1996–2014 9,850,964 9,304,795 0.64
Per person-year
1993–2014 8996 9723 0.23
1996–2014 8725 10,091 0.045
Data from 1993 to 1996 were assessed separately because of missing data
Table 2 Direct costs of specific healthcare services per individual per
year in the two treatment groups
Costs Mean yearly healthcare
costs per individual (€)
p value
Intensive Conventional
Outpatient services (from 1996)
CVD 92 136 0.087
Not CVD 1177 1211 0.99
Total 1269 1347 0.92
Inpatient admissions services
1993–1995
CVD 1290 2015 0.72
Not CVD 3712 2361 0.29
Total 5003 4375 0.89
From 1996
CVD 1338 2262 0.0048
Not CVD 2957 3509 0.43
Total 4295 5771 0.028
1993–2014
CVD 1331 2213 0.0024
Not CVD 3079 3281 0.63
Total 4410 5494 0.042
Prescription drugs
1993–1995 5071 3410 <0.0001
From 1996 2680 2387 0.0006
Primary healthcare sector
(from 1993)
433 514 <0.0001
As not all data from 1993 to 1995 are available, the periods before and
after 1996 are reported separately. ‘Outpatient services’ includes any ex-
penses related to consultations and treatment at a hospital that are not an
admission. ‘Inpatient admissions services’ includes any expenses related
to hospital admissions. ‘Prescription drugs’ includes any expenses related
to prescribed medication. ‘Primary healthcare sector’ includes any ex-
penses related to consultations with, or treatments from, a GP or
specialised medical professional not employed at a hospital, such as an
ophthalmologist
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Additionally, outpatient and inpatient services were split
into two groups: expenses related to CVD and expenses not
related to CVD (see Table 2). CVDwas defined in accordance
with a previous Steno-2 study publication [8].
Data sources and definitions Data on costs were gathered
from Danish health registries and were calculated as total di-
rect medical costs, costs per person-year as well as mean an-
nual expenses. The National Patient Registry contains data on
inpatient and outpatient services, which can be linked to the
Danish Case Mix System (Diagnosis-Related Groups, DRG),
thereby allowing the associated costs to be calculated [13, 14].
Expenses were retrieved for the periods 1993–2014 and
1996–2014, depending on availability of data. As data on
inpatient expenses were only available from 1996, costs of
inpatient services during 1993–1995 were imputed to the en-
tire study period dataset using data on number of admission
days in 1993–1995 multiplied by the mean price per day of
admission. The calculated mean costs are based on the costs
per day of admission during 1996–1998 and calculated for
each chapter of the International Statistical Classification of
Diseases and Related Health Problems, 10th revision (ICD-
10; http://apps.who.int/classifications/icd10/browse/2016/en).
Data on expenses for outpatient visits and prescription
drugs were not available before 1996. Drug expenses from
1996 were calculated by multiplying the retail price with the
prescribed quantity. These data are available from the Danish
Medicines Agency. As data were not available before 1996, it
was not possible to include the observed values for outpatient
costs and medical expenses for the period 1993–1995, and
therefore we performed a secondary analysis covering the pe-
riod 1996–2014 in addition to the primary analysis covering
the full follow-up period. To mitigate the potential bias from
unavailable data on prescription medicines for the period
1993–1995, we imputed data on expenses for prescription
medicines in 1996 (stratified for treatment randomisation
group, age group and sex) to the period 1993–1995. Because
of the stepwise introduction of medicines during the period
from baseline to 1995, we anticipate that this approach over-
estimates the real costs associated with prescription medicines.
Data on primary healthcare expenses are available from
1993 and were retrieved from the Danish National Health
Insurance Service Registry. All expenses were retrieved pro-
spectively from the index date, i.e. year 1 was defined as the
first 12 months after index date—the date of the specific indi-
vidual’s enrolment in the study—year 2 as the next 12months,
and so forth. The analysis followed the index year, not calen-
dar year, as the index year was either 1993 or 1994. This
means that observation period 1 was not in the same calendar
year for all individuals.
To mitigate missing data on outpatient services and medi-
cation from before 1996, numbers from an overview of med-
ication use and consultations in the two treatment groups in
1993–1995 (Table 3) were used as indicators of the differ-
ences between the two groups when registry data were not
available.
All costs were converted to euros (using a conversion fac-
tor of 7.45 Danish kroner [DKK] per €) and adjusted to 2015
price levels using the consumer price index.
Statistics The statistical significance of the differences in costs
between the two treatment groups was assessed by bootstrap t
test analysis with 10,000 resamples. At baseline, the two treat-
ment groups were well balanced for demographic variables
and risk factor levels, and thus we did not control for con-
founders [8, 12].
In Figs 1 and 2 there appears to be a peak in costs during
year 4, but this is an artefact stemming from the aggregation of
data from years 3 and 4 in some individuals. Smoothed mean
cost curves were constructed using locally weighted
scatterplot smoothing (LOWESS) with a bandwidth of 0.4.
In Fig. 2a, the hazard of death was calculated using a
weighted kernel-density estimate with a default bandwidth,
i.e. as a rolling mean of the hazard in the adjacent time period.
Figure 4 was constructed using all cumulative cardiovascular
events, amputations, end-stage renal disease and blindness
events per individual included (i.e. multiple events per indi-
vidual allowed).
The data used for these analyses were those collected and
previously reported for the long-term follow-up of clinical
outcomes and survival [8]. Statistical analyses were per-
formed blinded for treatment allocation. SAS version 9.4
was used for the statistical analyses, while figures were con-
structed using STATA version 15 (STATA, College Station,
TX, USA).
Results
Each group comprised 80 randomised individuals. Selected
baseline characteristics are presented in Table 4. The intensi-
fied treatment group was observed for a total of 1310 person-
years and the conventional therapy group for 1108 person-
years.
We found no statistically significant difference in total di-
rect medical costs between the two groups for the entire
follow-up period (1993–2014). The total costs in the intensi-
fied treatment group were €12,126,900 compared with
€11,181,700 in the conventional treatment group (p = 0.48)
(see Table 1). In the same period, the cost per person-year
was €8996 in the intensified treatment group and €9723 in
the conventional treatment group (p = 0.23) (see Table 1).
For the partial follow-up period (1996–2014), no signifi-
cant difference in total costs was found between the two
groups. The total costs were €9,850,964 in the intensified
treatment group and €9,304,795 in the conventional treatment
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group (p = 0.64). The mean cost per person-year was lower in
the intensified therapy group for the period 1996–2014, with
an expense per person-year of €8725 in the intensified treat-
ment group and €10,091 in the conventional treatment group
(p = 0.045).
Table 2 shows an overview of the mean annual expenses
per person in the intensified and conventional treatment
groups, respectively, in the different categories. In the intensi-
fied therapy group, yearly expenses for prescription drugs
were higher than in the conventional therapy group. Using
the imputed data from 1993–1995, we found that the average
yearly costs of prescription drugs during this period 1993–
1995 were higher in the intensified treatment group compared
with the conventional treatment group (p < 0.0001). The same
pattern was seen during the remaining 18 years of follow-up,
p = 0.0006. In contrast, yearly expenses for primary care and
inpatient admissions were significantly lower in the intensi-
fied therapy group compared with the conventional therapy
group (p < 0.0001 and p = 0.042, respectively). The difference
in yearly inpatient health costs was driven by increased costs
for CVD-related admissions in the conventional treatment
group (p = 0.0024). We found no significant differences in
yearly expenses for outpatient costs per person (p = 0.92).
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Fig. 1 Yearly mean direct medical costs per individual (in €) in the two
original treatment groups, starting at baseline in 1993. Data are the yearly
costs for the group divided by the number of individuals in the group in
that year. The peak at 4 years is an artefact from the aggregation of data
from years 3 and 4 in some individuals. Solid line, intensified therapy
group; dashed line, conventional therapy group
Table 3 Courses, consultations
and medication during the years
1993–1995
Intervention Intensive group
(n = 80)
Conventional group
(n = 80)
Difference
Courses and traininga
Dietary guidance (group sessions) (h) 32 0 32
Dietary guidance (individual session) (h) 2 1 1
Smoking cessation course (group session) (h) 15 0 15
Medical consultationsb
Number of yearly medical consultations 5 4c 1c
Medicationd
Sulfonylurea, n (%) 40 (51) 38 (48) 2
Metformin, n (%) 41 (53) 17 (21) 24
Insulin, n (%) 25 (32) 20 (25) 5
Statin, n (%) 4 (5) 1 (1) 3
ACE inhibitor, n (%) 76 (97) 19 (24) 57
Thiazide diuretic, n (%) 29 (37) 4 (5) 25
Loop diuretic, n (%) 11 (14) 12 (15) −1
Calcium antagonist, n (%) 19 (24) 9 (11) 10
Beta-blocker, n (%) 3 (4) 0 (0) 3
a Total number of education hours spent in the treatment groups during the period from baseline (1993) until the
end of 1995
bYearly number of medical consultations from baseline until the end of 1995 in the two treatment groups. All
individuals in the conventional treatment group had consultations with their GP, except for 12 individuals receiv-
ing insulin treatment at the time of inclusion and 20 individuals at the end of 1995. The frequency of visits to GPs
was assessed by questionnaire
c Individuals in the conventional treatment group had consultations in primary care and not in outpatient clinics
(unless they were insulin treated), as in the intensified treatment group
dNumber of individuals in each treatment group treated with different groups of medications. Data comprise self-
reported drug intake assessed at the study follow-up visit in 1995. All study participants provided data. At the
study follow-up visit in 1995 there were 80 individuals in the conventional treatment group and 78 individuals in
the intensive treatment group
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When observing the annual costs per individual (Fig. 1),
the two treatment groups have similar expenditures during the
first 8 years. After 8 years, the yearly costs per individual rise
steeply in the conventional treatment group, but stay essen-
tially unchanged in the intensified treatment group. After
15 years, however, the yearly costs in the intensified treatment
group start to increase, resembling the increasing costs of the
conventional treatment at year 8. Figure 2 shows yearly costs
and mortality hazard curves for people in the two treatment
arms compared; it appears that increased costs follow mortal-
ity rates as a proxy of higher level of morbidity (prior to
death). These findings are mirrored in the cumulative costs
(Fig. 3). This pattern reflects our previous finding that CVD
and mortality were delayed by about 8 years in the intensified
therapy group [8]. After 17 years, however, the slope of the
conventional treatment group starts to flatten, corresponding
with the declining yearly costs seen in Fig. 1, and the cumu-
lated costs of the two groups start converging, meeting at year
19. Hereafter, the intensified treatment group has the highest
cumulative costs, reflecting the higher number of persons
alive at the end of the follow-up period in the intensified
treatment group (n = 42 in the intensified treatment group
and n = 24 in the conventional treatment group).
Discussion
The overall conclusion of the 21.2 years of follow-up in the
Steno-2 study was that intensified multifactorial intervention
increased lifespan by a median of 7.9 years and similarly
postponed incident CVD by 8.1 years [8]. In the present post
hoc analysis of the total direct medical costs in the Steno-2
study, we show that intensified multifactorial intervention in
individuals with type 2 diabetes and microalbuminuria is cost-
neutral compared with conventional multifactorial interven-
tion over 21.2 years of follow-up. Furthermore, we demon-
strate that the cost per person-year was lower in the intensified
therapy group compared with the conventional treatment
group in the period 1996–2014, which is the period where
complete data were available. We found that the main driver
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Fig. 2 (a) Risk of death in the intensified therapy group (solid line) and in
the conventional therapy group (dashed line). The graphs are plotted to
start after baseline and are truncated before the end of follow-up because
no deaths occurred in those periods, hence the hazard was not calculated.
(b) Yearly direct health costs (as in Fig. 1), with data smoothed.
Comparing the two graphs shows similar trends (with allowance for mi-
nor delay in the cost curve because of the way data were collected).
Increasing mortality is followed closely by increased expenditure,
reflecting increased morbidity prior to death
Table 4 Baseline demographic data
Characteristic Baseline demographics (1993)
Intensive
(n = 80)
Conventional
(n = 80)
Age, years, mean ± SD 54.9 ± 7.2 55.2 ± 7.2
Age range, years 37–67 42–67
Proportion male sex, % 79 70
Known diabetes duration,
years, median (range)
4 (0–30) 6 (0–29)
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Fig. 3 Total direct medical costs for all individuals in each treatment
group. Solid line, intensified therapy group; dashed line, conventional
therapy group
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of the reduced cost per person-year in the intensified therapy
group was inpatient care consequent to CVD admission be-
cause the total number of events in the conventional treatment
group was double that in the intensified treatment group [8].
These results support our hypothesis that the increased
costs of medication and more frequent outpatient contacts
early in the disease course associated with a more intensive
treatment regimen were offset by the lower risk of late com-
plications and associated health costs.
Based on the non-significant difference in total costs
between groups for the full follow-up of approximately
€1,000,000 for the 202 more person-years in the intensive
therapy group during follow-up, a rough estimate of €5000
per life-year gained could be calculated. Despite this calcula-
tion not being performed in a formal manner because of data
limitations and not being corrected for quality of life (which
would yield a cost per quality-adjusted life-year [QALY] out-
come), this figure suggests that intensified multifaceted inter-
vention in high-risk individuals with type 2 diabetes is highly
feasible when balancing healthcare costs and treatment bene-
fits in a Danish healthcare setting.
As the Steno-2 study included high-risk individuals with
type 2 diabetes and microalbuminuria, findings from this anal-
ysis may not be generalisable. However, recently published
real-world evidence demonstrates an improved prognosis of
individuals with type 2 diabetes over recent decades,
reflecting the widespread implementation of intensified mul-
tifactorial approaches to management of type 2 diabetes in
general [7, 15].
After 8 years, we observed an acceleration in costs in the
conventional therapy group. This probably reflects individuals
in the conventional treatment group accruing more non-fatal
events, adding to their overall morbidity and resulting in an
increased need for and use of medication, as well as more
frequent outpatient visits (Fig. 2). The intensification of the
diabetes treatment regimen after 7.8 years may also have con-
tributed to increased costs.
After about 17 years, there was a steep decline in the yearly
expenses per individual in the conventional treatment group.
During the later years, however, the sample sizes of the two
treatment arms diminished and, as a result of this, a single indi-
vidual had a higher influence on the overall results. Therefore,
when analysing and interpreting the fluctuations in expenses
towards the end of the study period, much caution should be
taken, as the death of a single, yet health-cost-demanding indi-
vidual (e.g. one in chronic renal replacement therapy) may have
had a considerable impact on the total health expenses.
Expenses for individuals in chronic dialysis treatment have
been imputed in the overall analyses, but the requirement for
anonymity meant it was not possible to analyse this specific
complication separately.
In the analyses, we used high-quality Danish registries con-
taining complete information covering all individuals in the
majority of the study period, the direct medical costs from
the primary and secondary health sector and the use of drugs.
However, the costs of prescribed medication and outpatient
services were unavailable for the first 3 years after
randomisation. The costs of inpatient admission services from
1993 to 1995 were estimated based on the number of admis-
sion days and themean daily costs for an admission in a certain
ICD10 grouping. However, the majority of complications oc-
curred after the first 3 years of intervention, as shown in Fig. 4,
whichmeans the potential for bias from incomplete data is low.
At the end of the first 3 years, the largest differences in use
of medication between the intensified treatment group and the
conventional treatment group were seen for metformin (differ-
ence = 24 individuals), ACE inhibitors (difference = 57 indi-
viduals), thiazide diuretics (difference = 25 individuals) and,
to a lesser extent, calcium antagonists (difference = 10 individ-
uals). All these drugs were non-generic in the majority of the
formal intervention period. For medical consultations during
1993–1995, the consultations in the conventional treatment
group were mainly done in the primary sector and are thus
already accounted for in all analyses. However, individuals
in the conventional treatment group who were using insulin
treatment were seen in outpatient clinics on average five times
yearly, as in the intensified treatment group (n = 20 at the end
of 1995). Therefore, the consultations of the 20 individuals in
the conventional treatment group along with the consultations
in the intensified treatment group are not accounted for in the
primary analysis during this period.
In 2008, we reported a cost-effectiveness analysis using
modelled data in the same Steno-2 cohort based on data from
the initial 13 years of observation and projecting clinical and
cost outcomes over participant lifetimes [11]. It was anticipat-
ed that intensified multifactorial treatment in an outpatient
setting would be more expensive than conventional treatment
over a period of 30 years, primarily because of increased med-
ication costs and specialised treatment. This is somewhat in
line with the actual results of the current study, showing that
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the intensified treatment was associated with higher medica-
tion expenses and slightly more consultations.
In the above-mentioned cost-effectiveness analysis, an in-
cremental cost-effectiveness ratio (ICER) of €2538 per QALY
was calculated, which was considered cost-effective [11].
Because a direct QALY measure was not included in the
Steno-2 study, the two sets of analysis outcomes are not di-
rectly comparable. However, in the present study, the in-
creased lifespan and cost-neutrality align well with the pre-
dicted low cost per QALY gained.
In our study, we were not able to collect data on producti-
vity, tertiary care or rehabilitation, which presumably
accounted for substantial costs. The total costs of tertiary care
may increase following intensified treatment, as individuals
live longer. Conversely, the reduced incidence of strokes, am-
putations, end-stage renal disease, blindness and other dis-
abling organ complications in the intensified treatment group
might result in a longer productive period as part of the work
force [16]. Similarly, a reduction in the need for rehabilitation
and tertiary care in the originally intensively treated indivi-
duals may point to a smaller financial burden for society.
The emergence of generic drugs for treating all the major
risk factors (hyperglycaemia, hypertension, dyslipidaemia and
increased platelet aggregation and hypercoagulation) will
allow most individuals with type 2 diabetes to benefit from
an intervention regimen similar to the intensified therapy
group, with costs of pharmaceutical drugs vastly reduced
compared with the original 7.8 years of intensified interven-
tion in the Steno-2 study. This therapeutic approachmay allow
for improvements in the prognosis of people with type 2 dia-
betes in low-income settings.
Since the completion of the Steno-2 study, guidelines for
the treatment of type 2 diabetes have emphasised the impor-
tance of multiple risk factor intervention [17]. Consequently,
the risk for major CVD events in this population has decreased
[7]. However, it is evident from recent large clinical trials that a
substantial proportion of individuals are not treated according
to guidelines. In the LEADER (Liraglutide Effect and Action
in Diabetes: Evaluation of Cardiovascular Outcome Results)
and EMPA-REG OUTCOME trials, despite enrolled individ-
uals being at very high risk of micro- and macrovascular com-
plications, around 25% of participants were not treated with
statins, around 20% were not receiving renin–angiotensin–al-
dosterone (RAAS) inhibitors and 10–20% were not receiving
anticoagulants, in contrast with guideline recommendations
[18–21]. In addition, newer drugs, such as glucagon-like pep-
tide 1 (GLP-1) analogues and sodium/glucose cotransporter 2
(SGLT-2) inhibitors, have a special role in the treatment algo-
rithm of high-risk patients with type 2 diabetes [22].
Therefore, we believe that the comparison between intensified
therapy and less-intensive therapy is still relevant today.
Nevertheless, the overall results from the present analysis
from the Steno-2 study demonstrate that increased use of
economic resources spent on an early multipronged intensive
treatment strategy (e.g. on medication and specialist consulta-
tions) prevents diabetes-related complications, whereas con-
ventional treatment requires spending the same amount, but
on treating quality- and length-of-life-reducing complications.
With continuous drug development and consequently new
drugs available to further reduce risk, drugs will likely continue
to be an important expense in future diabetes care. Still, diabe-
tes complications are the main driver of direct medical costs in
type 2 diabetes [4] and therefore it is important for decision-
makers to incorporate the assessment of clinical outcomes of
importance, and not just direct costs and surrogate outcome
markers, in the evaluation of new treatment opportunities.
In conclusion, over 21.2 years of follow-up, the total direct
costs of an intensified multifactorial intervention, which led to
a disease-free life-length improvement of about 8 years, were
similar to those of conventional treatment. The major limita-
tion of the study was missing data on expenses related to
prescription medicines and inpatient admissions during the
first 3 years of the trial, the missing data on tertiary care and
rehabilitation and the small study sample size. However, our
data clearly suggest that investing in early intensified interven-
tion in high-risk individuals with type 2 diabetes in a Danish
healthcare setting will pay for itself over time through reduc-
tions in the cost of treating diabetes complications.
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